| Biomechanical forces promote immune regulatory function of bone marrow mesenchymal stromal cells MF Diaz, AB Vaidya, SM Evans, HJ Lee, BM Aertker, AJ Alexander, ... Stem Cells 35 (5), 1259-1272, 2017 | 61 | 2017 |
| CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells N Hebbar, R Epperly, A Vaidya, U Thanekar, SE Moore, M Umeda, J Ma, ... Nature Communications 13 (1), 587, 2022 | 53 | 2022 |
| CD28 and 41BB Costimulation enhances the effector function of CD19-specific engager T cells MP Velasquez, A Szoor, A Vaidya, A Thakkar, P Nguyen, MF Wu, ... Cancer Immunology Research, 2017 | 36 | 2017 |
| T cell-activating mesenchymal stem cells as a biotherapeutic for HCC A Szoor, A Vaidya, MP Velasquez, Z Mei, DL Galvan, D Torres, A Gee, ... Molecular Therapy-Oncolytics 6, 69-79, 2017 | 35 | 2017 |
| Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies A Freiwan, JT Zoine, JC Crawford, A Vaidya, SA Schattgen, JA Myers, ... Blood, The Journal of the American Society of Hematology 140 (25), 2684-2696, 2022 | 34 | 2022 |
| The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing JM Riberdy, S Zhou, F Zheng, YI Kim, J Moore, A Vaidya, RE Throm, ... Molecular Therapy - Methods and Clinical Development, 2020 | 21 | 2020 |
| Advancing beyond the twists and turns of T cell exhaustion in cancer V van der Heide, E Humblin, A Vaidya, AO Kamphorst Science translational medicine 14 (670), eabo4997, 2022 | 17 | 2022 |
| Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1+ PD-1+ CD8 T cells E Humblin, I Korpas, J Lu, D Filipescu, V van der Heide, S Goldstein, ... Science immunology 8 (86), eadg0878, 2023 | 11 | 2023 |
| Transgenic Expression of IL15 retains CD123-redirected T-cells in a less differentiated state resulting in improved anti-AML activity in autologous AML PDX models H Mu-Mosley, L Ostermann, M Muftuoglu, A Vaidya, C Bonifant, ... Frontiers in Immunology, 1687, 2022 | 8 | 2022 |
| Two-pronged cell therapy for B-cell malignancies: engineering NK cells to target CD22 and redirect bystander T cells to CD19 MP Velasquez, A Szoor, CL Bonifant, A Vaidya, L Brunetti, MC Gundry, ... Blood 128 (22), 4560, 2016 | 7 | 2016 |
| Improving the anti-acute myeloid leukemia activity of CD123-specific Engager T cells by MyD88 and CD40 costimulation A Vaidya, E Doherty, X Wu, S Huang, N Hebbar, U Thanekar, CL Bonifant, ... Haematologica, 2022 | 6 | 2022 |
| IL15 expressing CD123-targeted engager T-cell therapy for adult acute myeloid leukemia H Mu, H Ma, A Vaidya, CL Bonifant, S Gottschalk, MP Velasquez, ... Blood 132, 2724, 2018 | 6 | 2018 |
| Two-pronged Cell Therapy: Engineering NK cells to target CD22 and redirect bystander T cells to CD19 for the adoptive immunotherapy of B-cell malignancies A Szoor, MP Velasquez, CL Bonifant, A Vaidya, L Brunetti, M Gundry, ... The Journal of Immunology 198 (1_Supplement), 198.6-198.6, 2017 | 4 | 2017 |
| Autologous CD19-CAR T-cells for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients: an initial report from an institutional phase I/II study A Talleur, A Qudeimat, T Lockey, A Gaboriault, D Langfitt, JY Metais, ... Clinical Lymphoma, Myeloma and Leukemia 19, S265, 2019 | 2 | 2019 |
| GRP78 Is Expressed on the Cell Surface of Pediatric AML Blasts and Can be Targeted with GRP78-CAR T Cells without Toxicity to Hematopoietic Progenitor Cells N Hebbar, R Epperly, A Vaidya, S Huang, C Cheng, S Gottschalk, ... The American Society of Hematology, 2020 | 1 | 2020 |
| Transgenic expression of IL15 in CD123-specific BiTE-secreting engager T-cells results in improved anti-AML activity H Mu-Mosley, LB Ostermann, M Muftuoglu, W Schober, NB Patel, ... Blood 134, 3917, 2019 | 1 | 2019 |
| Improving CD123-Targeted T-Cell Therapy for Acute Myeloid Leukemia E Doherty, A Vaidya, C Bonifant, M Mata, AM Leen, S Gottschalk, ... Biology of Blood and Marrow Transplantation 24 (3), S232, 2018 | 1 | 2018 |
| Grp78 targeted adoptive cell therapy MP Velasquez, S Gottschalk, N Hebbar, R Epperly, A Vaidya US Patent App. 17/919,728, 2023 | | 2023 |
| The Preprint Club-A cross-institutional, community-based approach to peer reviewing FC Richter, E Gea-Mallorquí, N Ruffin, N Vabret bioRxiv, 2023.01. 04.522570, 2023 | | 2023 |
| Naturally Occurring CD7-T Cells Mark a Functional Effector and Persistent CAR T Cell Population JT Zoine, A Freiwan, JC Crawford, A Vaidya, SA Schattgen, JA Myers, ... MOLECULAR THERAPY 30 (4), 46-47, 2022 | | 2022 |
Mireya Paulina VelasquezSt Jude Children's Research Hospital在 stjude.org 的电子邮件经过验证
